Evidence Hub

The Clinical stady of moxifloxacin and levofloxacin in the treatment of community-acquired pneumonia for the treatment community-acquired pneumonia

Meiling Liao

Journal of Clinical Pulmonary Medicine, 2011

120 participants

Abstract

Objective To study the clinical Value in moxifloxacin and levofloxacin for the treatment of community-acquired pneumonia(CAP).Methods 120 patients of CAP were chosen and divided randomly into team of moxifloxacin and team of levofloxacin.These two categories of patients were given separate treatments for 7 days which were analyzed and appraised by the cost-effect method in pharmacoeconomic research.Results The Overall clinical effective rate for team of moxifloxacin was 98.33% and for team of levofloxcine was 71.67%;the bacterial clearance rate for team of moxifloxacin was 91.67% and for team of levofloxcine was 65.57%;Occurrence of the adverse reaction for team moxifloxacin was 8.33% and for team levofloxcine was 13.33%,and the cost-effectiveness ratios were 21.87 and 10.26.Conclusion The overall clinical effective rate and the bacterial clearance rate of team moxifloxacin is better than that of team levofloxcine.Moxifloxacin for the treatment CAP is the preferred plan in the clinic.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free